CD8A and neoplasm: The Synthekine company iscurrently conducting preclinical trials for STK-026, which are expected todemonstrate its capacity to activate tumor-infiltrating CD8+ T cellsand myeloid cells, as well as its antitumor efficacy and pharmacodynamicprofile.